{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:30:11Z","timestamp":1793500211424,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtho.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:26:31Z","timestamp":1762331191000},"page":"1565-1568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-2420","authenticated-orcid":false,"given":"Haining","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.08.009_bib1","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2025.08.009_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2025.08.009_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtho.2024.12.014","article-title":"A perspective on the MARS2 trial","volume":"20","author":"Lim","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.08.009_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib8","article-title":"Real-world outcomes of patients with malignant pleural mesothelioma receiving a combination of ipilimumab and nivolumab as first- or later-line treatment","volume":"5","author":"Schmid","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.08.009_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2024.01.017","article-title":"Immunotherapy is a good standard option for patients with malignant pleural mesothelioma, despite the real-world results from Australia","volume":"19","author":"Smesseim","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the real-world results from Australia, immunotherapy is not a good option for patients with mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lungcan.2022.08.019","article-title":"Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?","volume":"173","author":"Disselhorst","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.08.009_bib12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2025.06.018","article-title":"Immune composition and immunotherapy outcomes of mesothelioma with BAP1, CDKN2A, MTAP, and NF2 alterations","volume":"20","author":"Dagogo-Jack","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib13","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.08.009_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib16","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jtho.2022.05.005","article-title":"Somatic BAP1 loss as a predictive biomarker of overall survival in patients with malignant pleural mesothelioma treated with chemotherapy","volume":"17","author":"Ghafoor","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib17","doi-asserted-by":"crossref","first-page":"8471","DOI":"10.1038\/ncomms9471","article-title":"BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5","volume":"6","author":"Qin","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.08.009_bib18","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1038\/s41467-018-05085-9","article-title":"Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis","volume":"9","author":"Asada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.08.009_bib19","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41598-023-29017-w","article-title":"Targeting BAP1 with small compound inhibitor for colon cancer treatment","volume":"13","author":"Kang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2025.08.009_bib20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib21","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jtho.2025.06.020","article-title":"Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations","volume":"20","author":"Carbone","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.009_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","article-title":"Niraparib plus dostarlimab in pleural mesothelioma or non-small cell lung cancer harboring HRR mutations: interim results of the UNITO-001 phase II prospective trial","volume":"30","author":"Passiglia","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425010135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425010135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:24Z","timestamp":1793499984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425010135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1556086425010135"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.08.009","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.06.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}